Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2025 the Company granted inducement awards to ...

Investing.com -- Shares of Incyte (NASDAQ: INCY) climbed 7% today after the biopharmaceutical company announced that multiple ...

Incyte Corporation (NASDAQ:INCY) saw its stock surge 7% after the company announced that multiple research presentations, ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing ...

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly ...

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab ...